Strategies for identifying predictive biomarkers and subgroups with enhanced treatment effect in clinical trials using SIDES

Journal of Biopharmaceutical Statistics

Volumn 24, Issue 1, 2014, Pages 130-153

  Lipkovich, Ilya ^a   Dmitrienko, Alex ^a  

^a IQVIA   (United States)

Author keywords

Biomarker discovery; Predictive biomarkers; SIDES method; Subgroup identification; Variable importance

Indexed keywords

BILIRUBIN; BIOLOGICAL MARKER; CREATININE; INTERLEUKIN 6;

ALGORITHM; ANALYTIC METHOD; APACHE; ARTICLE; CLINICAL TRIAL (TOPIC); DATA BASE; GLASGOW COMA SCALE; HUMAN; MORTALITY; OUTCOME VARIABLE; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SCREENING TEST; SEPSIS; SIGNAL NOISE RATIO; SIMULATION; SUBGROUP IDENTIFICATION BASED ON DIFFERENTIAL EFFECT SEARCH; THERAPY EFFECT; THROMBOCYTE;

ALGORITHMS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RESEARCH DESIGN; SEPSIS; SIGNAL-TO-NOISE RATIO; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84891758815     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2013.856024     Document Type: Article

References (24)

1. Breiman, L. (2001). Random forests. Machine Learning. 45:5-32.
2. Brookes, S. T., Whitley, E., Peters, T. J., Mulheran, P. A., Egger, M., Davey Smith, G. (2001). Subgroup analyses in randomised controlled trials: Quantifying the risks of false-positives and false-negatives. Health Technology Assessment 5:1-56.
3. Brugger, W., Triller, N., Blasinska-Morawiec, M., Curescu, S., Sakalauskas, R., Manikhas, G. M., Mazieres, J., Whittom, R., Ward, C., Mayne, K., Trunzer, K., Cappuzzo, F. (2011). Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced nonsmall-cell lung cancer. Journal of Clinical Oncology 29:4113-4120.
4. Cai, T., Tian, L., Wong, P., Wei, L. J. (2011). Analysis of randomized comparative clinical trial data for personalized treatment selections. Biostatistics 12:270-282.
5. Dmitrienko, A., Bretz, F., Westfall, P. H., Troendle, J., Wiens, B. L., Tamhane, A. C., Hsu, J. C. (2009). Multiple testing methodology. In: Dmitrienko, A., Tamhane, A. C., Bretz, F. eds., Multiple Testing Problems in Pharmaceutical Statistics. New York, NY: Chapman and Hall/CRC Press, pp. 35-98.
6. Freidlin, B., Simon, R. (2005). Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clinical Cancer Research 11:7872-7878.
7. Freidlin, B., Jiang, W., Simon, R. (2010). Adaptive signature design: The cross-validated adaptive signature design. Clinical Cancer Research 16:691-698.
8. Food and Drug Administration. (2012). Guidance for industry: Enrichment strategies for clinical trials to support approval of human drugs and biological products. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatory Information/Guidances/UCM332181.pdf
9. Foster, J. C., Taylor, J. M. C., Ruberg, S. J. (2011). Subgroup identification from randomized clinical trial data. Statistics in Medicine 30:2867-2880.
10. Gunter, L., Zhu, J., Murphy, S. (2011). Variable selection for qualitative interactions in personalized medicine while controlling the familywise error rate. Journal of Biopharmaceutical Statistics 21:1063-1078.
11. Hardin, D. S., Rohwer, R. D., Curtis, B. H., Zagar, A., Chen, L., Boye, K. S., Jiang, H. H., Lipkovich, I. A. (2013). Understanding heterogeneity in response to antidiabetes treatment: A post hoc analysis using SIDES, a subgroup identification algorithm. Journal of Diabetes Science and Technology 7:420-430.
12. Kehl, V., Ulm, K. (2006). Responder identification in clinical trials with censored data. Computational Statistics and Data Analysis 50:1338-1355.
13. Knaus, W. A., Draper, E. A., Wagner, D. P., Zimmerman, J. E. (1985). APACHE II: A severity of disease classification system. Critical Care Medicine 13:818-829.
14. Lipkovich, I., Dmitrienko, A., Denne, J., Enas, G. (2011). Subgroup Identification based on Differential Effect Search (SIDES): A recursive partitioning method for establishing response to treatment in patient subpopulations. Statistics in Medicine 30:2601-2621.
15. Millen, B., Dmitrienko, A., Ruberg, S., Shen, L. (2012). A statistical framework for decision making in confirmatory multipopulation tailoring clinical trials. Drug Information Journal 46:647-656.
16. Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J. J., Chewaskulyong, B., Jiang, H., Duffield, E. L., Watkins, C. L., Armour, A. A., Fukuoka, M. (2009). Gefitinib or carboplatin paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine 361:947-957.
17. Rothwell, P. M. (2005). Subgroup analysis in randomized controlled trials: Importance, indications, and interpretation. Lancet 365:176-186.
18. Simon, R., Wang, S. J. (2006). Use of genomic signatures in therapeutics development in oncology and other diseases. Pharmacogenomics Journal 6:166-173.
19. Su, X., Tsai, C. L., Wang, H., Nickerson, D. M., Li, B. (2009). Subgroup analysis via recursive partitioning. Journal of Machine Learning Research 10:141-158.
20. Sun, X., Briel, M., Walter, S. D., Guyatt, G. H. (2010). Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. British Medical Journal 340:c117, 850-854.
21. Varadhan, R., Segal, J. B., Boyd, C. M., Wu, A. W., Weiss, C. O. (2013). A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research. Journal of Clinical Epidemiology 66:818-825.
22. Wang, R., Lagakos, S. W. (2009). Inference after variable selection using restricted permutation methods. Canadian Journal of Statistics 37:625-644.
23. Wang, S. J., O'Neill, R. T., Hung, H. M. J. (2007). Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics 6: 227-244.
24. Westfall, P. H., Young, S. S. (1993). Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment. New York, NY: John Wiley.